The Federal Drug Administration's advisers meet Thursday to discuss whether to grant Pfizer emergency use authorization for the company's coronavirus vaccine, which has been found to be highly effective thus far in clinical trials.
The authorization would allow Americans to begin receiving their first doses of the two-dose treatment within days, marking the beginning of the largest vaccination effort in U.S. history.
The meeting was scheduled to begin at 9 a.m. The FDA is set to begin an in-depth panel discussion at 3 p.m., wrapping with votes on questions posed by its advisers. It is expected to adjourn shortly after 5 p.m.:
- Mass. Vaccine Rollout Plan Will Be In 3 Phases. Here's When You Could Get Yours
- U.S. Government May Find It Hard To Get More Doses Of Pfizer's COVID-19 Vaccine
- Pfizer Is Already Producing Millions Of Doses Of Its Vaccine. A Crucial Ingredient Comes From Mass.
- 'The Perfect Storm': How Vaccine Misinformation Spread To The Mainstream